May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
After its efficacy was demonstrated in a clinical trial, the US Food and Drug Administration approved a new treatment options for adult patients with 2 types of poor-prognosis acute myeloid leukemia.
The US Food and Drug Administration recently approved a new treatment option for patients with relapsed or refractory acute myeloid leukemia who have IDH2 mutations.
